Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.

@article{Imaoka2016PostadjuvantCC,
  title={Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.},
  author={Hiroshi Imaoka and Yasuhiro Shimizu and Y Senda and Seiji Natsume and Nobuyuki Mizuno and Kazuo Hara and Susumu Hijioka and Nobuhiro Hieda and Masahiro Tajika and Tsutomu Tanaka and Makoto Ishihara and Yasumasa Niwa and Kenji Yamao},
  journal={Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]},
  year={2016},
  volume={16 4},
  pages={
          658-64
        }
}
BACKGROUND Carbohydrate antigen 19-9 (CA19-9) is a widely used tumor marker for pancreatic ductal adenocarcinoma (PDAC). In addition, several studies have reported the utility of both pre- and postoperative CA19-9 levels as prognostic factors in resectable PDAC. However, little is known about the implications of post-adjuvant chemotherapy (AC) CA19-9 levels. The purpose of this study was to examine the utility of the post-AC CA19-9 level as a prognostic marker for relapse-free survival (RFS) in… CONTINUE READING
BETA

Similar Papers

Loading similar papers…